CF PharmTech, Inc. (02652.HK)価格

CF PharmTech, Inc engages in the research, development, production and sale of respiratory diseases pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 574 full-time employees. The company went IPO on 2025-10-08. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The firm's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The firm mainly conducts its business in the domestic market.